Longevity PapersAbout
← All papers
RESEARCH PAPER / 2026-08-31

A cross-species drug-discovery platform to accelerate the identification of lifespan-extending interventions.

Kevin Perez, Lucas Schoenfeldt, Grace B Phelps, Alberto Parras, Jonas Morin, Carla Pinto, Sebastien Guilmot, Tadeu Oliveira, Maria Silveira, Luca Dolfi, Alejandro Ocampo

EPITERNA, 1066 Épalinges, Switzerland; Institute of Oncology Research (IOR), 6500 Bellinzona, Switzerland; Università della Svizzera Italiana, 6900 Lugano, Switzerland. Electronic address: [email protected]. · pubmed

Abstract

We develop an integrated, high-throughput platform to evaluate pharmacological lifespan-extending interventions across five model organisms spanning unicellular to mammalian biology including yeast, nematodes, fruit flies, killifish, and mice. By combining automated imaging, miniaturized assays, and deep-learning-based death detection, we evaluate over 400 compounds across thousands of conditions. In S. cerevisiae, a miniaturized PI/flow cytometry CLS assay enables scalable screening and identifies key assay confounders, while in C. elegans and D. melanogaster, compact imaging platforms coupled to YOLO-based detection provide a no-transfer, high-throughput survival scoring, and capture compound-, diet-, and sex-dependent effects. In killifish, we develop an in-house drug-pellet formulation for standardized oral delivery in large cohorts, and in mice we combine longitudinal lifespan studies with home-cage activity monitoring to assess late-life interventions. Cross-species integration identifies multi-species geroprotectors and reveals convergence on known and novel conserved longevity pathways, illustrating how this scalable framework can prioritize interventions with high translational potential.

The following analysis is generated by AI and may contain errors. It is separate from the authors’ abstract and is not peer review.

Research summary

The paper demonstrates that an integrated, high-throughput cross-species platform can efficiently screen hundreds of compounds to identify conserved geroprotectors with high translational potential. This is relevant because it directly addresses the bottleneck in aging research by providing a scalable, automated infrastructure to test interventions that extend lifespan across diverse biological models, thereby accelerating the discovery of root-cause aging therapies rather than treating symptoms.

Author of this paper? Send a correction.